曲美他嗪对急性冠脉综合征患者血清炎性因子水平的影响

Effect of trimetazidine on the inflammatory factor in the patients with acute coronary syndrome

目的探讨曲美他嗪治疗急性冠脉综合征(ACS)的机制。方法将同期收治的100例ACS患者随机分为观察组和对照组各50例,两组均予ACS常规治疗,在此基础上观察组口服曲美他嗪,连续4周。分别测定两组治疗前后血清C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)水平。结果治疗后观察组血清CRP、TNF-α、IL-6水平显著低于治疗前及对照组(P<0.01)。结论曲美他嗪可通过抗炎作用治疗ACS。

Objective To investigatc the curative mechanism of trimetazidine to patients with acute coronary syndrome. Methods One hundred patients with actue coronary syndrome were randomly divided into observed group（n = 50） and control group （ n = 50）, both groups were given routine treatment, and the observed group was also treated with trimetazidine. 4 weeks later, CRP,TNF-α,IL-6 were measured inflammatory. Results Levels of CRP, TNF-α, IL-6 in observed group were significantly lower than that before treatment and in the control group （P 〈 0.01 ）. Conclusion Trimetazidine has anti-inflammatory effects to the patients with acute coronary syndrome.